Literature DB >> 15765116

Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.

F Larosa1, C Marmier, E Robinet, C Ferrand, P Saas, E Deconinck, C-E Bulabois, P-S Rohrlich, K Ledu, P Helias, P Tiberghien, J-Y Cahn.   

Abstract

Peripheral blood stem cell transplantation after reduced-intensity conditioning (RIC-PBSCT) regimen is an alternative to conventional regimens with less immediate toxicity. Since immune recovery is of crucial importance for the control of infections, we retrospectively studied the recovery of T-, B- and NK cell subsets in 20 consecutive patients undergoing RIC-PBSCT. We also studied the thymic output using T-cell receptor excision circle assay. Engraftment was rapid and few infectious complications were seen: three early (before 2.5 months) cases of asymptomatic cytomegalovirus reactivation, two late Gram-negative bacterial infections and no fungal infection. While CD4+ T-cell reconstitution was slow, CD8+ T-cell counts were close to normal values at 4 months. Median CD19+ B-cell counts reached normal values at 11 months. Rapid CD56+ NK cell reconstitution was noticed as early as 1.5 months. Low T-cell receptor excision circle numbers and preponderance of memory-type subsets among T cells further suggested that CD8+ T-cell reconstitution resulted predominantly from peripheral expansion and that thymic-dependent reconstitution was severely impaired. In conclusion, large peripheral T-cell expansion may compensate for late thymic-dependent lymphopoiesis, and may, with other factors such as NK and B-cell reconstitution and careful antiinfectious prophylaxis, help limit the incidence of severe infections after RIC-PBSCT.

Entities:  

Mesh:

Year:  2005        PMID: 15765116     DOI: 10.1038/sj.bmt.1704889

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic hematopoietic stem cell transplantation following conventional or reduced-dose conditioning.

Authors:  Olaf Penack; Lars Fischer; Andrea Stroux; Chiara Gentilini; Axel Nogai; Arne Muessig; Susanne Ganepola; Thoralf Lange; Constanze Kliem; Olga Marinets; Igor Wolfgang Blau; Eckhard Thiel; Lutz Uhareka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

2.  CCL25 increases thymopoiesis after androgen withdrawal.

Authors:  Kirsten M Williams; Philip J Lucas; Catherine V Bare; Jiun Wang; Yu-Waye Chu; Ezekiel Tayler; Veena Kapoor; Ronald E Gress
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 3.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

4.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

5.  Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation.

Authors:  Didier Ducloux; Cécile Courivaud; Jamal Bamoulid; Bérengère Vivet; Aline Chabroux; Marina Deschamps; Jean-Michel Rebibou; Christophe Ferrand; Jean-Marc Chalopin; Pierre Tiberghien; Philippe Saas
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

6.  The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.

Authors:  Roberta Fedele; Massimo Martino; Cristina Garreffa; Giuseppe Messina; Giuseppe Console; Domenica Princi; Antonella Dattola; Tiziana Moscato; Elisabetta Massara; Elisa Spiniello; Giuseppe Irrera; Pasquale Iacopino
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

Review 7.  Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Ronald E Gress
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

8.  Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.

Authors:  Franck Saint-Marcoux; Bernard Royer; Jean Debord; Fabrice Larosa; Faezeh Legrand; Eric Deconinck; Jean-Pierre Kantelip; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 9.  A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.

Authors:  Erden Atilla; Pınar Ataca Atilla; Taner Demirer
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

10.  Peripheral blood lymphocyte responses to cytomegalovirus seropositivity after allogeneic-hematopoietic stem cell transplantation.

Authors:  Jiexin Zhang; Xian Chen; Guodong Rong; Ting Xu; Hong Zhao; Dan Chen; Lei Wu; Peijun Huang; Fang Wang
Journal:  Onco Targets Ther       Date:  2018-08-24       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.